Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis. Reversal with VP-16 and indomethacin
- 15 November 1987
- Vol. 60 (10) , 2388-2393
- https://doi.org/10.1002/1097-0142(19871115)60:10<2388::aid-cncr2820601007>3.0.co;2-a
Abstract
Clinicopathologic and histopathologic evidence of both endoperoxidation with hyperprostaglandinemia and hyperlipidemia in a 5-week-old infant with a hemophagocytic syndrome is reported. Institution of histiocytolytic (VP-16) and cyclo-oxygenase inhibitor (indomethacin) therapies returned the prostaglandin levels and lipid profile to a nearly normal state coincidental with clinical recovery. It appears that by reducing the cell mass of histiocytes and controlling the over-production of prostaglandins, some types of hemophagocytic syndrome can be reversed.This publication has 17 references indexed in Scilit:
- Use of VP-16–213 in the treatment of familial erythrophagocytic lymphohistiocytosisCancer, 1986
- Reactive Hemophagocytic SyndromePediatric Pathology, 1985
- The Familial HistiocytosesPediatric Pathology, 1985
- Familial erythrophagocytic lymphohistiocytosis: An association with serum lipid abnormalitiesThe Journal of Pediatrics, 1983
- Virus associated hemophagocytic syndromeHuman Pathology, 1981
- Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213Cancer, 1980
- Virus-associated hemophagocytic syndromeA benign histiocytic proliferation distinct from malignant histiocytosisCancer, 1979
- Familial erythrophagocytic lymphohistiocytosis.report of two cases and clinicopathologic reviewCancer, 1976
- Microsomal Lipid Peroxidation: Morphological CharacterizationScience, 1972
- Familial Haemophagocytic ReticulosisArchives of Disease in Childhood, 1952